Engagement of Veterans With Lung Cancer
This research study will help our understanding of whether additional support for Veterans with lung cancer can improve their quality of life.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Mar 3, 2026 · Source: ClinicalTrials.gov
The study is currently accepting participants.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Health Services Research
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Palo Alto Veterans Institute for Research
- Interventions being studied
- Behavioral: Lay Health Worker (LHW) Planning; Other: Usual Care Group
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
1. Veteran patients with diagnosis of any stage of lung cancer; 2. 18 years of age or older; 3. English- or Spanish-speaking; 4. can self-administer questionnaires in English or Spanish; 5. valid telephone number; 6. receiving oncology care at participating sites; 7. currently newly diagnosed or receiving or having completed systemic anti-cancer therapy and/or radiation therapy within 12 months, defined as oral, injection, or intravenous therapy (chemotherapy, targeted therapy, or immunotherapy)
1. no capacity to consent; 2. actively receiving hospice care
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Veterans Affairs Palo Alto Health Care System (VAPAHCS)Palo Alto, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 3, 2026. Always confirm current availability with the study team.